Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) (NCT04526691)

🧪 Interventions in This Study

• Datopotamab deruxtecan (DRUG)
• KEYTRUDA® (DRUG)
• Carboplatin (DRUG)
• Cisplatin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (24 Sites)

• Mayo Clinic — Scottsdale, Arizona
• City of Hope — Duarte, California
• Johns Hopkins Kimmel Cancer Center — Washington D.C., District of Columbia
• Mayo Clinic — Jacksonville, Florida
• Johns Hopkins Kimmel Cancer Center at Bayview — Baltimore, Maryland
• The Skip Viragh Outpatient Cancer Building — Baltimore, Maryland
• Mayo Clinic — Rochester, Minnesota
• Quantum Santa Fe — Santa Fe, New Mexico
• NEXT Oncology — San Antonio, Texas
• Instituto Europeo Di Oncologica — Milan,
• Azienda Ospedaliera San Gerardo — Monza,
• Istituto Nazionale Tumori Fondazione G. Pascale di Napoli Struttura di Oncologia — Naples,
• National Cancer Center Hospital East — Chiba,
• National Cancer Center Hospital — Tokyo,
• Showa Medical University Hospital — Tokyo,
• H. Vall Hebrón (Vall Hebron Institut de Oncologia - VHIO) — Barcelona,
• START Madrid - Hospital Universitario Fundacion Jimenez Diaz — Madrid,
• Hospital Universitario 12 de Octubre — Madrid,
• (CIOCC-START) Hospital Universitario HM Sanchinarro — Madrid,
• Hospital Puerta de Hierro — Majadahonda,
• Chung Shan Medical University Hospital — Taichung,
• Taichung Veterans General Hospital — Taichung,
• National Cheng Kung University Hospital NCKUH — Tainan,
• National Taiwan University Hospital NTUH — Taipei,

📞 Contact the Study Coordinator

Phone: (800) 664-4580

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced or Metastatic NSCLC

• Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer — La Jolla, California

Explore by condition: All Advanced or Metastatic NSCLC clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.